title: CD95 (FAS/APO-1) antigen is a new prognostic marker of blast cells of acute lymphoblastic leukaemia patients.
abstract: We analyzed CD95(Fas/APO-1) antigen expression on bone marrow blasts in 38 children with acute lymphoblastic leukemia (ALL) receiving a treatment in the Department of Leukaemias at the Cancer Research Center in 1987-1989 years (n = 22) and in 1994-1997 years (n = 16). CD95 antigen expression was studied by monoclonal antibodies (MoAbs) IPO-4 in indirect immunofluorescence analysis. CD95 antigen was expressed on 35.8 +/- 7.5% bone marrow blasts, most frequently (63.6%) in the clinically favourable Pre-B ALL. Only in this group CD95 antigen expression was correlated with CD10 antigen expression that has a positive influence to the time of complete remission in ALL patients. Our data showed that CD95 expression on blast cells is a favourable prognostic sign, associated with increased relapse-free and total survival. On the contrary, the absence of CD95 antigen on blasts is an unfavourable sign for disease evolution.
authors.affiliation: Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia.
authors.lastname: Baryshnikov AYu
authors.forename: E R
authors.initials: ER
authors.lastname: Polosukhina
authors.forename: N N
authors.initials: NN
authors.lastname: Tupitsin
authors.forename: N V
authors.initials: NV
authors.lastname: Gavrikova
authors.lastname: Andreeva LYu
authors.forename: T N
authors.initials: TN
authors.lastname: Zabotina
authors.forename: S A
authors.initials: SA
authors.lastname: Mayakova
authors.forename: V I
authors.initials: VI
authors.lastname: Kurmashov
authors.forename: A B
authors.initials: AB
authors.lastname: Syrkin
authors.forename: Z G
authors.initials: ZG
authors.lastname: Kadagidze
authors.lastname: Blochin DYu
authors.lastname: Shishkin YuV
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000032:analysis*; D001752:Blast Crisis / Q000473:pathology*; D001854:Bone Marrow Cells / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D016130:Immunophenotyping; D007223:Infant; D008297:Male; D015260:Neprilysin / Q000032:analysis; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D016019:Survival Analysis; D019014:fas Receptor / Q000032:analysis*
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D014408:Biomarkers, Tumor; D019014:fas Receptor; D015260:Neprilysin